People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cure Pharmaceutical Holding Corp. | — | Pharmaceuticals | Series B | $31.5M | $343.2M | 2020 |
Ruben King-Shaw at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ruben King-Shaw on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Bell | 1 | 5 |
| Alex Katz | 1 | 5 |
| Gene Salkind | 1 | 5 |
| Robert Davidson | 1 | 3 |
| CHARLES BERMAN | 1 | 3 |
| Edward Maliski | 1 | 2 |
| Mark Udell | 1 | 2 |
| Lauren Chung | 1 | 2 |
| JOSH HELD | 1 | 2 |
| Anya Goldin | 1 | 1 |
| William Yuan | 1 | 1 |
| Nancy Duitch | 1 | 1 |
| Mike Redard | 1 | 1 |
| Alan Einstein | 1 | 1 |
| Jessica Rousset | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.